Concourse Financial Group Securities, Inc. Protalix Bio Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.67 Billion
- Q4 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
4.58MCall Options Held
40.9KPut Options Held
5.3K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.12MShares$2.88 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL732KShares$1.89 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny388KShares$1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$859,5810.0% of portfolio
-
Gsa Capital Partners LLP London, X0306KShares$788,8320.04% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $128M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...